Literature DB >> 355030

Insulin-binding antibody: reaction differences with bovine and porcine insulins.

A B Kurtz, J A Matthews, J D Nabarro.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 355030     DOI: 10.1007/bf01219322

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  13 in total

1.  INSULIN RESISTANCE. RESPONSE TO INSULIN FROM VARIOUS ANIMAL SOURCES, INCLUDING HUMAN.

Authors:  B R BOSHELL; J C BARRETT; A S WILENSKY; T B PATTON
Journal:  Diabetes       Date:  1964 Mar-Apr       Impact factor: 9.461

2.  RELATIONSHIP BETWEEN DIFFERENTIAL ANTIBODY BINDING CAPACITY AND CLINICAL REQUIREMENTS OF BEEF AND PORT INSULIN.

Authors:  J G DEVLIN; T G BRIEN
Journal:  Metabolism       Date:  1965-09       Impact factor: 8.694

3.  Species-specificity of human antibeef, pork insulin serum.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

4.  Quantitative aspects of the reaction between insulin and insulin-binding antibody.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

5.  IMMUNOLOGIC STUDIES IN INSULIN RESISTANCE I. REPORT OF A CASE EXHIBITING VARIATIONS IN RESISTANCE AND ALLERGY TO INSULIN.

Authors:  F C Lowell
Journal:  J Clin Invest       Date:  1944-03       Impact factor: 14.808

6.  Hazards of monocomponent insulins.

Authors:  A W Logie; J M Stowers
Journal:  Br Med J       Date:  1976-04-10

7.  Risk of changing from ox to pig insulin.

Authors:  B A Young; T D Kellock
Journal:  Lancet       Date:  1966-10-22       Impact factor: 79.321

8.  Insulin receptors in human circulating cells and fibroblasts.

Authors:  J R Gavin; J Roth; P Jen; P Freychet
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

9.  Insulin binding capacity in patients changed from conventional to highly purified insulins. An indicator of likely response.

Authors:  B E Mustaffa; P R Daggett; J D Nabarro
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

10.  Effect of insulin antibodies on free and total plasma-insulin.

Authors:  A B Kurtz; B E Mustaffa; P R Daggett; J D Nabarro
Journal:  Lancet       Date:  1977-07-09       Impact factor: 79.321

View more
  8 in total

1.  The newer insulins.

Authors:  J G Devlin; O Maguire; V Parameswaran
Journal:  Ir J Med Sci       Date:  1979       Impact factor: 1.568

2.  Circulating IgG antibody to protamine in patients treated with protamine-insulins.

Authors:  A B Kurtz; R S Gray; S Markanday; J D Nabarro
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

Review 3.  Circulating insulin-binding antibodies.

Authors:  A B Kurtz; J D Nabarro
Journal:  Diabetologia       Date:  1980-10       Impact factor: 10.122

4.  Factitious diabetes and antibody mediated resistance to beef insulin.

Authors:  A B Kurtz; M G Harrington; J A Matthews; J D Nabarro
Journal:  Diabetologia       Date:  1979-01       Impact factor: 10.122

Review 5.  Adverse effects of exogenous insulin. Clinical features, management and prevention.

Authors:  A W Patrick; G Williams
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

6.  Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.

Authors:  A B Kurtz; J A Matthews; B E Mustaffa; P R Daggett; J D Nabarro
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

7.  Influence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabetics.

Authors:  R S Gray; P Cowan; U di Mario; R A Elton; B F Clarke; L J Duncan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-08

8.  The bioavailability of circulating antibody-bound insulin following insulin withdrawal in Type 1 (insulin-dependent) diabetes.

Authors:  N J Vaughan; J A Matthews; A B Kurtz; J D Nabarro
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.